Details of the Drug

General Information of Drug (ID: DMMWZET)

Drug Name
Dexamethasone
Synonyms
Adexone; Anaflogistico; Aphtasolon; Aphthasolone; Auxiron; Azium; Calonat; Corson; Corsone; Cortisumman; DXM; Decacort; Decacortin; Decaderm; Decadron; Decagel; Decaject; Decalix; Decameth; Decasone; Decaspray; Dectancyl; Dekacort; Deltafluorene; Dergramin; Deronil; Desadrene; Desametasone; Desamethasone; Desameton; Deseronil; Dexacort; Dexacortal; Dexacortin; Dexadeltone; Dexafarma; Dexair; Dexalona; Dexaltin; Dexametasona; Dexameth; Dexamethansone; Dexamethasonum; Dexamethazone; Dexamonozon; Dexapolcort; Dexaprol; Dexason; Dexasone; Dexinolon; Dexinoral; Dexone; Dexonium; Dexpak; Dextelan; Dezone; Dinormon; Dxms; Fluormethylprednisolone; Fluormone; Fluorocort; Fortecortin; Gammacorten; Hexadecadrol; Hexadrol; IontoDex; Loverine; Luxazone; Maxidex; Mediamethasone; Methylfluorprednisolone; Mexidex; Millicorten; Mymethasone; Oradexon; Policort; Posurdex; Prodex; Spoloven; Superprednol; Turbinaire; Visumetazone; Alcon Brand of Dexamethasone; Bisu DS; Desametasone [DCIT]; Dexa Mamallet; Dexamethasone Base; Dexamethasone Intensol; Dexamethasone alcohol; ECR Brand of Dexamethasone; Foy Brand of Dexamethasone; Hexadrol Elixir; Hexadrol Tablets; ICN Brand of Dexamethasone; Lokalison F; Merck Brand of Dexamethasone; Pet Derm III; Prednisolon F; Prednisolone F; Sunia Sol D; Dexone 4; MK 125; Merz Brand 1 of Dexamethasone; Merz Brand 2 of Dexamethasone; Aeroseb-D; Aeroseb-Dex; Azium (Veterinary); Decadron (TN); Decadron Tablets, Elixir; Decadron, Dexamethasone; Decadron-LA; Dex-ide; Dexa-Cortidelt;Dexa-Cortisyl; Dexa-Mamallet; Dexa-Scheroson; Dexa-sine; Dexacen-4; Dexametasona [INN-Spanish]; Dexamethasonum [INN-Latin]; Dexone 0.5; Dexone 0.75; Dexone 1.5; Hl-dex; Isopto-Dex; OTO-104; Ocu-trol;Pet-Derm Iii; SK-Dexamethasone; Decaject L.A.; Dexamethasone [INN:BAN:JAN]; Decaject-L.A.; Dexamethasone (JP15/USP/INN); Delta1-9alpha-Fluoro-16alpha-methylcortisol; Delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol; (3H)-Dexamethasone; 1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone; 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol; 16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone; 16-alpha-Methyl-9-alpha-fluoroprednisolone; 16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol; 16.alpha.-Methyl-9.alpha.-fluoroprednisolone; 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol; 16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone; 16alpha-Methyl-9alpha-fluoroprednisolone; 9-alpha-Fluoro-16-alpha-methylprednisolone; 9.alpha.-Fluoro-16.alpha.-methylprednisolone; 9A-FLUORO-16BETA-METHYLPREDNISOLONE; 9alpha-Fluoro-16alpha-methylprednisolone
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Approved [1], [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 392.5
Topological Polar Surface Area (xlogp) 1.9
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.3 mL/min/kg [4]
Elimination
2.6% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.7 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3276 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.32% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.94 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.092 mg/mL [3]
Chemical Identifiers
Formula
C22H29FO5
IUPAC Name
(8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C
InChI
InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
InChIKey
UREBDLICKHMUKA-CXSFZGCWSA-N
Cross-matching ID
PubChem CID
5743
ChEBI ID
CHEBI:41879
CAS Number
50-02-2
DrugBank ID
DB01234
TTD ID
D0IT2G
VARIDT ID
DR00215
INTEDE ID
DR0451
ACDINA ID
D00185

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Agonist [6], [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Peptide transporter 1 (SLC15A1) DT9G7XN S15A1_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [12]
Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DEDH7FP DHI2_HUMAN Substrate [13]
Carboxylesterase 2 (CES2) DETHCPD EST2_HUMAN Substrate [14]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Rheumatoid arthritis
ICD Disease Classification FA20
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
P-glycoprotein 1 (ABCB1) DTP P-GP 7.23E-01 -8.20E-02 -3.22E-01
Peptide transporter 1 (SLC15A1) DTP PEPT1 3.21E-01 -1.66E-01 -8.74E-01
Carboxylesterase 2 (CES2) DME CES2 8.63E-02 1.29E-01 5.47E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 5.82E-01 -6.00E-02 -2.69E-01
Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DME HSD11B2 2.15E-01 -2.26E-01 -6.33E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 9.85E-01 2.24E-02 7.33E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dexamethasone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Salsalate DM13P4C Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Dexamethasone and Salsalate. Rheumatoid arthritis [FA20] [61]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Canakinumab. Rheumatoid arthritis [FA20] [62]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Rilonacept. Rheumatoid arthritis [FA20] [62]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Dexamethasone and Golimumab. Rheumatoid arthritis [FA20] [63]
Coadministration of a Drug Treating the Disease Different from Dexamethasone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Dexamethasone due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [64]
Midostaurin DMI6E0R Moderate Increased metabolism of Dexamethasone caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [65]
Oliceridine DM6MDCF Major Increased metabolism of Dexamethasone caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [66]
Ivabradine DM0L594 Moderate Increased metabolism of Dexamethasone caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [67]
Dronedarone DMA8FS5 Moderate Increased metabolism of Dexamethasone caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [68]
Bedaquiline DM3906J Major Increased metabolism of Dexamethasone caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [67]
Posaconazole DMUL5EW Moderate Decreased metabolism of Dexamethasone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [69]
Levalbuterol DM5YBO1 Minor Increased risk of hypokalemia by the combination of Dexamethasone and Levalbuterol. Asthma [CA23] [70]
Pirbuterol DMI5678 Minor Increased risk of hypokalemia by the combination of Dexamethasone and Pirbuterol. Asthma [CA23] [69]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Roflumilast. Asthma [CA23] [67]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Dexamethasone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [71]
ABT-492 DMJFD2I Major Increased risk of tendinitis/tendon rupture by the combination of Dexamethasone and ABT-492. Bacterial infection [1A00-1C4Z] [72]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Dexamethasone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [73]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Dexamethasone caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [74]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Dexamethasone caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [75]
Lapatinib DM3BH1Y Moderate Increased metabolism of Dexamethasone caused by Lapatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
HKI-272 DM6QOVN Major Increased metabolism of Dexamethasone caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
LY2835219 DM93VBZ Moderate Increased metabolism of Dexamethasone caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [76]
Tucatinib DMBESUA Moderate Increased metabolism of Dexamethasone caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [77]
Palbociclib DMD7L94 Moderate Increased metabolism of Dexamethasone caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Bosutinib DMTI8YE Major Increased metabolism of Dexamethasone caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [78]
Macitentan DMP79A1 Moderate Increased metabolism of Dexamethasone caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [79]
PF-04449913 DMSB068 Major Increased metabolism of Dexamethasone caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [80]
Vilanterol DMF5EK1 Minor Increased risk of hypokalemia by the combination of Dexamethasone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [70]
Indacaterol DMQJHR7 Minor Increased risk of hypokalemia by the combination of Dexamethasone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [69]
Arformoterol DMYM974 Minor Increased risk of hypokalemia by the combination of Dexamethasone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [69]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Dexamethasone caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [81]
Regorafenib DMHSY1I Moderate Increased metabolism of Dexamethasone caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [82]
Intedanib DMSTA36 Major Increased metabolism of Dexamethasone caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [83]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Dexamethasone and Pancuronium. Corneal disease [9A76-9A78] [69]
Osilodrostat DMIJC9X Moderate Increased metabolism of Dexamethasone caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [84]
Ivacaftor DMZC1HS Moderate Increased metabolism of Dexamethasone caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [85]
MK-8228 DMOB58Q Moderate Decreased metabolism of Dexamethasone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [86]
Rivaroxaban DMQMBZ1 Moderate Increased metabolism of Dexamethasone caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [87]
Vilazodone DM4LECQ Moderate Increased metabolism of Dexamethasone caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [88]
Vortioxetine DM6F1PU Moderate Increased metabolism of Dexamethasone caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [89]
Cenobamate DMGOVHA Moderate Increased metabolism of Dexamethasone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [90]
Stiripentol DMMSDOY Moderate Increased metabolism of Dexamethasone caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Dexamethasone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [91]
Tazemetostat DMWP1BH Major Increased metabolism of Dexamethasone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [92]
Solifenacin DMG592Q Moderate Increased metabolism of Dexamethasone caused by Solifenacin mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [93]
Mirabegron DMS1GYT Minor Increased metabolism of Dexamethasone caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [94]
Ripretinib DM958QB Moderate Increased metabolism of Dexamethasone caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [70]
Avapritinib DMK2GZX Major Increased metabolism of Dexamethasone caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [67]
Boceprevir DMBSHMF Moderate Increased metabolism of Dexamethasone caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [95]
Simeprevir DMLUA9D Major Increased metabolism of Dexamethasone caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [96]
Telaprevir DMMRV29 Moderate Increased metabolism of Dexamethasone caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [95]
Pretomanid DMDYA31 Major Increased metabolism of Dexamethasone caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [97]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Dexamethasone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Dexamethasone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Dolutegravir DMCZGRE Minor Increased metabolism of Dexamethasone caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Elvitegravir DMG9B1U Moderate Increased metabolism of Dexamethasone caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Etravirine DMGV8QU Moderate Increased metabolism of Dexamethasone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Rilpivirine DMJ0QOW Major Increased metabolism of Dexamethasone caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Darunavir DMN3GCH Moderate Decreased metabolism of Dexamethasone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Maraviroc DMTL94F Moderate Increased metabolism of Dexamethasone caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [70]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Dexamethasone and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [101]
Tolvaptan DMIWFRL Moderate Increased metabolism of Dexamethasone caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [67]
Suvorexant DM0E6S3 Moderate Increased metabolism of Dexamethasone caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [102]
Amobarbital DM0GQ8N Moderate Increased metabolism of Dexamethasone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [103]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Dexamethasone caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [104]
ITI-007 DMUQ1DO Major Increased metabolism of Dexamethasone caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [105]
Naloxegol DML0B41 Moderate Increased metabolism of Dexamethasone caused by Naloxegol mediated induction of CYP450 enzyme. Large intestine motility disorder [DB32] [106]
Pemigatinib DM819JF Major Increased metabolism of Dexamethasone caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [67]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Denosumab. Low bone mass disorder [FB83] [107]
Crizotinib DM4F29C Moderate Increased metabolism of Dexamethasone caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [108]
Brigatinib DM7W94S Major Increased metabolism of Dexamethasone caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [70]
Ceritinib DMB920Z Moderate Increased metabolism of Dexamethasone caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [109]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Dexamethasone caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [110]
PF-06463922 DMKM7EW Major Increased metabolism of Dexamethasone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [111]
Osimertinib DMRJLAT Moderate Increased metabolism of Dexamethasone caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [112]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Dexamethasone due to the transporter induction by BIBW 2992. Lung cancer [2C25] [113]
Pralsetinib DMWU0I2 Moderate Increased metabolism of Dexamethasone caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [114]
Capmatinib DMYCXKL Major Increased metabolism of Dexamethasone caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [115]
Selpercatinib DMZR15V Major Increased metabolism of Dexamethasone caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [67]
Artemether DM48QOT Moderate Increased metabolism of Dexamethasone caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [70]
Idelalisib DM602WT Moderate Increased metabolism of Dexamethasone caused by Idelalisib mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [116]
GDC-0199 DMH0QKA Major Increased metabolism of Dexamethasone caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [117]
IPI-145 DMWA24P Moderate Increased metabolism of Dexamethasone caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [118]
Acalabrutinib DM7GCVW Moderate Increased metabolism of Dexamethasone caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [119]
Ponatinib DMYGJQO Moderate Increased metabolism of Dexamethasone caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [70]
Arry-162 DM1P6FR Moderate Increased metabolism of Dexamethasone caused by Arry-162 mediated induction of CYP450 enzyme. Melanoma [2C30] [70]
Vemurafenib DM62UG5 Moderate Increased metabolism of Dexamethasone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [120]
Nivolumab DMAB9QE Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Nivolumab. Melanoma [2C30] [69]
Selumetinib DMC7W6R Major Increased metabolism of Dexamethasone caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [121]
Pembrolizumab DMFQEA6 Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Pembrolizumab. Melanoma [2C30] [69]
Ipilimumab DMJTIYK Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Ipilimumab. Melanoma [2C30] [69]
Cemiplimab DMKMJHE Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Cemiplimab. Melanoma [2C30] [69]
LGX818 DMNQXV8 Major Increased metabolism of Dexamethasone caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [122]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Dexamethasone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [67]
Ubrogepant DM749I3 Moderate Increased metabolism of Dexamethasone caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [123]
Rimegepant DMHOAUG Major Increased metabolism of Dexamethasone caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [124]
Flibanserin DM70DTN Moderate Increased metabolism of Dexamethasone caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [125]
Panobinostat DM58WKG Moderate Increased metabolism of Dexamethasone caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [126]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Tecfidera. Multiple sclerosis [8A40] [127]
Siponimod DM2R86O Major Increased metabolism of Dexamethasone caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [70]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Dexamethasone and Fingolimod. Multiple sclerosis [8A40] [128]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Ocrelizumab. Multiple sclerosis [8A40] [129]
Romidepsin DMT5GNL Moderate Increased metabolism of Dexamethasone caused by Romidepsin mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [130]
Fedratinib DM4ZBK6 Major Increased metabolism of Dexamethasone caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [67]
Nilotinib DM7HXWT Major Increased metabolism of Dexamethasone caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [131]
Ruxolitinib DM7Q98D Moderate Increased metabolism of Dexamethasone caused by Ruxolitinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [132]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [133]
Rolapitant DM8XP26 Moderate Increased metabolism of Dexamethasone caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [67]
Netupitant DMEKAYI Moderate Decreased metabolism of Dexamethasone caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [134]
E-2007 DMJDYNQ Moderate Increased metabolism of Dexamethasone caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [67]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Atezolizumab. Non-small cell lung cancer [2C25] [69]
Entrectinib DMMPTLH Major Increased metabolism of Dexamethasone caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [135]
S-297995 DM26IH8 Moderate Increased metabolism of Dexamethasone caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [67]
Olaparib DM8QB1D Major Increased metabolism of Dexamethasone caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [70]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Dexamethasone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [136]
Pimavanserin DMR7IVC Moderate Increased metabolism of Dexamethasone caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [137]
Abametapir DM2RX0I Moderate Decreased metabolism of Dexamethasone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [138]
Lefamulin DME6G97 Major Increased metabolism of Dexamethasone caused by Lefamulin mediated induction of CYP450 enzyme. Pneumonia [CA40] [139]
Choline salicylate DM8P137 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Dexamethasone and Choline salicylate. Postoperative inflammation [1A00-CA43] [61]
Ergonovine DM0VEC1 Moderate Increased metabolism of Dexamethasone caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [70]
Lonafarnib DMGM2Z6 Major Increased metabolism of Dexamethasone caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [140]
Enzalutamide DMGL19D Moderate Increased metabolism of Dexamethasone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [141]
Relugolix DMK7IWL Moderate Accelerated clearance of Dexamethasone due to the transporter induction by Relugolix. Prostate cancer [2C82] [142]
Darolutamide DMV7YFT Major Increased metabolism of Dexamethasone caused by Darolutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [143]
Silodosin DMJSBT6 Moderate Increased metabolism of Dexamethasone caused by Silodosin mediated induction of CYP450 enzyme. Prostate hyperplasia [GA90] [70]
Apremilast DMTWS9E Moderate Increased metabolism of Dexamethasone caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [144]
Riociguat DMXBLMP Moderate Increased metabolism of Dexamethasone caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [145]
Everolimus DM8X2EH Major Increased metabolism of Dexamethasone caused by Everolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [66]
Axitinib DMGVH6N Major Increased metabolism of Dexamethasone caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [146]
Temsirolimus DMS104F Major Increased metabolism of Dexamethasone caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [70]
Aripiprazole DM3NUMH Moderate Increased metabolism of Dexamethasone caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [147]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Dexamethasone when combined with Anthrax vaccine. Sepsis [1G40-1G41] [148]
Avanafil DM75CXN Moderate Increased metabolism of Dexamethasone caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [149]
Voxelotor DMCS6M5 Major Increased metabolism of Dexamethasone caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [150]
LDE225 DMM9F25 Major Increased metabolism of Dexamethasone caused by LDE225 mediated induction of CYP450 enzyme. Skin cancer [2C30-2C37] [151]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Dexamethasone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [67]
Larotrectinib DM26CQR Moderate Increased metabolism of Dexamethasone caused by Larotrectinib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [70]
Trabectedin DMG3Y89 Moderate Increased metabolism of Dexamethasone caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [67]
Armodafinil DMGB035 Moderate Increased metabolism of Dexamethasone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [152]
LEE011 DMMX75K Moderate Increased metabolism of Dexamethasone caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [70]
Vandetanib DMRICNP Moderate Increased metabolism of Dexamethasone caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [153]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Dexamethasone and Pitolisant. Somnolence [MG42] [67]
Fostamatinib DM6AUHV Moderate Increased metabolism of Dexamethasone caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [154]
Apixaban DM89JLN Moderate Increased metabolism of Dexamethasone caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [155]
Brilinta DMBR01X Moderate Increased metabolism of Dexamethasone caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [66]
Cabozantinib DMIYDT4 Moderate Increased metabolism of Dexamethasone caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [156]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Dexamethasone and Pipecuronium. Tonus and reflex abnormality [MB47] [69]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Dexamethasone and Vecuronium. Tonus and reflex abnormality [MB47] [69]
Linagliptin DMWFJTR Moderate Increased metabolism of Dexamethasone caused by Linagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [157]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Dexamethasone and Durvalumab. Ureteral cancer [2C92] [69]
Elagolix DMB2C0E Moderate Increased metabolism of Dexamethasone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [158]
⏷ Show the Full List of 147 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 1 E00263 19700 Colorant
Hydrazine yellow E00409 164825 Colorant
Quinoline yellow WS E00309 24671 Colorant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dexamethasone 6 mg tablet 6 mg Oral Tablet Oral
Dexamethasone 0.5 mg tablet 0.5 mg Oral Tablet Oral
Dexamethasone 0.75 mg tablet 0.75 mg Oral Tablet Oral
Dexamethasone 1.5 mg tablet 1.5 mg Oral Tablet Oral
Dexamethasone 4 mg tablet 4 mg Oral Tablet Oral
Dexamethasone 1 mg tablet 1 mg Oral Tablet Oral
Dexamethasone 2 mg tablet 2 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3447).
2 Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
7 Functional mineralocorticoid receptor (MR) gene variation influences the cortisol awakening response after dexamethasone. Psychoneuroendocrinology. 2010 Apr;35(3):339-49.
8 Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch Pharm Res. 2007 Apr;30(4):507-18.
9 Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605.
10 Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol. 1996 Mar;41(3):187-90.
11 Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
12 Cytotoxicity of chloroacetanilide herbicide alachlor in HepG2 cells independent of CYP3A4 and CYP3A7. Food Chem Toxicol. 2007 May;45(5):871-7.
13 Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
14 In vitro metabolism of dexamethasone cipecilate, a novel synthetic corticosteroid, in human liver and nasal mucosa. Xenobiotica. 2011 Oct;41(10):874-84.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
25 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
26 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
27 Drug Interactions Flockhart Table
28 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
29 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
30 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
31 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
32 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
33 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
34 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
35 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
36 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
37 Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3. Drug Metab Dispos. 2004 May;32(5):505-11.
38 Investigation of the metabolism of rufinamide and its interaction with valproate. Drug Metab Lett. 2011 Dec;5(4):280-9.
39 Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med. 2019 Jan 17;9(1). pii: E7.
40 Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem. 2013 Feb;405(5):1695-704.
41 Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol. 2005 Aug;35(1):89-101.
42 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
43 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
44 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
45 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
46 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
47 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
48 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
49 Interactions of amoxicillin and cefaclor with human renal organic anion and peptide transporters. Drug Metab Dispos. 2006 Apr;34(4):547-55.
50 Several hPepT1-transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Res Microbiol. 2017 Jun;168(5):443-449.
51 High-affinity interaction of sartans with H+/peptide transporters. Drug Metab Dispos. 2009 Jan;37(1):143-9.
52 The intestinal H+/peptide symporter PEPT1: structure-affinity relationships. Eur J Pharm Sci. 2004 Jan;21(1):53-60.
53 Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J Med Chem. 2005 Jun 30;48(13):4410-9.
54 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61.
55 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
56 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
57 Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
58 Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
59 PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
60 The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
61 Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
62 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
63 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
64 Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
65 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
66 Canadian Pharmacists Association.
67 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
68 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
69 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
70 Cerner Multum, Inc. "Australian Product Information.".
71 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
72 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
73 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
74 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
75 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
76 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
77 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
78 Product Information. Bosulif (bosutinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
79 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
80 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
81 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
82 Product Information. Stivarga (regorafenib). Bayer Pharmaceutical Inc, West Haven, CT.
83 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
84 Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
85 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
86 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
87 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
88 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
89 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
90 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
91 Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
92 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
93 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
94 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
95 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
96 Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
97 Product Information. Pretomanid (pretomanid). The Global Alliance for TB Drug Development, New York, NY.
98 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
99 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
100 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
101 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
102 Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
103 Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
104 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
105 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
106 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
107 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
108 Cerner Multum, Inc. "Canadian Product Information.".
109 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
110 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
111 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
112 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 Product Information. Gilotrif (afatinib). Boehringer Ingelheim, Ridgefield, CT.
114 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
115 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
116 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
117 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
118 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
119 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
120 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
121 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
122 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
123 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
124 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
125 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
126 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
127 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
128 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
129 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
130 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
131 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
132 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
133 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
134 Product Information. Akynzeo (netupitant-palonosetron). Eisai Inc, Woodcliff Lake, NJ.
135 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
136 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
137 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
138 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
139 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
140 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
141 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
142 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
143 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
144 Product Information. Otezla (apremilast). Celgene Corporation, Summit, NJ.
145 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
146 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
147 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
148 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
149 Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
150 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
151 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
152 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
153 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
154 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
155 Product Information. Eliquis (apixaban). Bristol-Myers Squibb Canada Inc, Montreal, IN.
156 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
157 Product Information. Tradjenta (linagliptin). Boehringer Ingelheim, Ridgefield, CT.
158 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.